Eurizon Capital SGR S.p.A. Invests $1.70 Million in Solventum Corporation $SOLV

Eurizon Capital SGR S.p.A. bought a new position in Solventum Corporation (NYSE:SOLV) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 21,475 shares of the company’s stock, valued at approximately $1,703,000.

Other institutional investors have also recently made changes to their positions in the company. LSV Asset Management lifted its holdings in shares of Solventum by 364.5% in the 3rd quarter. LSV Asset Management now owns 35,122 shares of the company’s stock worth $2,564,000 after acquiring an additional 27,561 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Solventum by 15.3% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 307,789 shares of the company’s stock worth $22,469,000 after acquiring an additional 40,812 shares during the last quarter. Davis Selected Advisers lifted its holdings in shares of Solventum by 0.5% in the 3rd quarter. Davis Selected Advisers now owns 5,517,611 shares of the company’s stock worth $402,786,000 after acquiring an additional 24,950 shares during the last quarter. Appleton Partners Inc. MA bought a new stake in shares of Solventum in the 4th quarter worth about $7,008,000. Finally, SG Americas Securities LLC lifted its holdings in shares of Solventum by 92.3% in the 4th quarter. SG Americas Securities LLC now owns 93,681 shares of the company’s stock worth $7,423,000 after acquiring an additional 44,970 shares during the last quarter.

Solventum Trading Up 0.7%

Shares of SOLV opened at $76.40 on Wednesday. Solventum Corporation has a 1-year low of $62.38 and a 1-year high of $88.20. The company has a 50-day moving average of $69.75 and a 200 day moving average of $75.08. The firm has a market capitalization of $13.23 billion, a price-to-earnings ratio of 9.36, a PEG ratio of 1.17 and a beta of 0.69. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75.

Solventum (NYSE:SOLV) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The company had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same quarter last year, the business posted $1.34 EPS. The firm’s revenue for the quarter was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, research analysts expect that Solventum Corporation will post 6.58 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on SOLV shares. Wedbush started coverage on shares of Solventum in a report on Friday, May 15th. They issued an “outperform” rating and a $94.00 target price for the company. Wells Fargo & Company decreased their price objective on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a report on Wednesday, May 6th. KeyCorp lifted their price objective on shares of Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Piper Sandler decreased their price objective on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Finally, Rothschild & Co Redburn started coverage on shares of Solventum in a report on Tuesday, March 24th. They set a “sell” rating and a $60.00 price objective for the company. Eight equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $84.25.

Insiders Place Their Bets

In other Solventum news, Director Amy Mcbride Wendell bought 1,475 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were acquired at an average price of $68.03 per share, with a total value of $100,344.25. Following the transaction, the director owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This trade represents a 41.39% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.24% of the stock is owned by insiders.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.